Affiliate files to sell 25,000 shares under Form 144

LQDA: An affiliate filed a Form 144 reporting proposed sales of 25,000 shares pursuant to resale notices.

Rhea-AI Filing Summary

LQDA: An affiliate filed a Form 144 reporting proposed sales of 25,000 shares pursuant to resale notices.

The filing also lists multiple completed 10b5-1 sales by SERENDIPITY BIOPHARMA LLC and a sale by ROGER JEFFS on dates between 04/09/2026 and 05/06/2026, with individual trade proceeds shown for each transaction.

Insights

Securities Attorney

Form 144 notice of proposed resale and detailed 10b5-1 sale records are provided.

The filing shows a reported proposed sale of 25,000 shares and a sequence of executed 10b5-1 transactions with per-trade proceeds listed. This is a routine affiliate resale/notice filing rather than new corporate action.

Cash‑flow treatment and the ultimate timing of any remaining resale depend on market execution and statutory resale rules; the excerpt lists trade dates and gross proceeds for each reported sale.

Key Figures

Proposed resale: 25,000 shares 05/06/2026 trade: 25,000 shares 05/05/2026 trade: 25,000 shares +4 more

7 metrics

Proposed resale 25,000 shares Form 144 top-line registered amount

05/06/2026 trade 25,000 shares 10b5-1 sale with proceeds $1,019,572.50

05/05/2026 trade 25,000 shares 10b5-1 sale with proceeds $1,002,592.50

04/17/2026 trade 18,839 shares 10b5-1 sale with proceeds $764,955.71

04/13/2026 trade 32,744 shares Sale by ROGER JEFFS with proceeds $1,256,387.28

04/14/2026 trade 3,300 shares 10b5-1 sale with proceeds $132,000.00

04/10/2026 trade 21,433 shares 10b5-1 sale with proceeds $859,876.96

Key Terms

Form 144, 10b5-1, gross proceeds

3 terms

Form 144 regulatory

"filed a Form 144 reporting proposed sales of 25,000 shares"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

10b5-1 regulatory

"10b5-1 Sales for SERENDIPITY BIOPHARMA LLC ..."

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

gross proceeds financial

"25000 | 1019572.50 (proceeds per trade listed)"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 for LQDA report?

It reports a proposed resale notice of 25,000 shares. The filing also lists completed 10b5-1 sales with dates and gross proceeds between 04/09/2026 and 05/06/2026.

Who executed the 10b5-1 sales listed in the LQDA filing?

The excerpt lists SERENDIPITY BIOPHARMA LLC as the primary 10b5-1 seller and a sale by ROGER JEFFS. Each trade entry includes date, share count, and gross proceeds.

How many shares and proceeds are shown for the 05/06/2026 trade?

The entry dated 05/06/2026 shows 25,000 shares with gross proceeds of $1,019,572.50 as listed in the filing excerpt.

Are the listed trades covered by a trading plan?

Yes; multiple entries are labeled as 10b5-1 Sales, indicating sales executed under a pre-established trading plan. The excerpt shows dates, share counts, and proceeds for those plan trades.

Does the filing specify who receives the sale proceeds?

The excerpt lists gross proceeds per trade but does not attribute receipt to a specific party beyond the named selling entities. Cash‑flow recipient details are not otherwise specified in the excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/07/2026 - 04:18 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001231615
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	LIQUIDIA CORPORATION
SEC File Number	001-39724
Address of Issuer	419 Davis Drive, Suite 100, Morrisville NORTH CAROLINA 27560
Phone	9193284400
Name of Person for Whose Account the Securities are To Be Sold	SERENDIPITY BIOPHARMA LLC
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25000	1053500.00	88114429	05/07/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/18/2020	Merger or Acquisition	Issuer			25000	11/18/2020	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	05/06/2026	25000	1019572.50
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	05/05/2026	25000	1002592.50
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/17/2026	18839	764955.71
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/16/2026	25000	1007800.00
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/15/2026	25000	1003522.50
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/14/2026	3300	132000.00
ROGER JEFFS 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/13/2026	32744	1256387.28
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/10/2026	21433	859876.96
10b5-1 Sales for SERENDIPITY BIOPHARMA LLC 419 Davis Drive, Suite 100, Morrisville NC 27560	Common	04/09/2026	25000	1002887.50

144: Remarks and Signature

Remarks
Date of Notice	05/07/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/05/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Roger Jeffs
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)